Provided by Tiger Trade Technology Pte. Ltd.

Merck

148.00
-0.3500-0.24%
Volume:1.66M
Turnover:245.03M
Market Cap:365.14B
PE:116.28
High:148.12
Open:147.11
Low:145.98
Close:148.35
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.38
T/O Rate:0.07%
Dividend:3.32
Dividend Rate:2.24%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.71
PE(LYR):20.33

Loading ...

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 10

Eikon Therapeutics Appoints Merck’s Johnny Bennett to Scientific Advisory Board

Reuters
·
Aug 10

Coinbase, GM, Delta, Merck, Applied Digital: Insider Shock

TIPRANKS
·
Aug 08

Zoetis Inc. Stock Slips 6.0%, Underperforms Peers

Dow Jones
·
Aug 08

Merck EVP Chirfi Guindo Disposes of 15,000 Common Shares Worth $1.97 Million

Reuters
·
Aug 08

Morning BID Americas-Dealjà Vu

Reuters
·
Aug 07

Merck KGaA (0O14) Receives a Buy from UBS

TIPRANKS
·
Aug 07

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Dow Jones
·
Aug 07

Merck Says US FDA Accepts Supplemental Biologics License Application to Expand Enflonsia's Indication

MT Newswires Live
·
Aug 06

Merck says FDA accepts sBLA for enflonsia

TIPRANKS
·
Aug 06

Merck Says FDA Accepts sBLA to Expand Enflonsia RSV Prevention to High-Risk Children Under 2 for Second Season

Reuters
·
Aug 06

Merck & Co - FDA Sets Pdufa Target Action Date of March 22, 2027 for Enflonsia Sbla

THOMSON REUTERS
·
Aug 06

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Aug 06

Merck Raises 2026 Profit Guidance, Beats Quarterly Estimates

Reuters
·
Aug 06

Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer

MT Newswires Live
·
Aug 05

Guggenheim Adjusts Merck Price Target to $146 From $145

MT Newswires Live
·
Aug 05

Merck On Track for $3 Billion in Share Repurchases in 2026, Morgan Stanley Says

MT Newswires Live
·
Aug 05

Merck announces Health Canada approval of KEYTRUDA for adults with MIBC

TIPRANKS
·
Aug 05

Health Canada Approves Keytruda® for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer Who are Ineligible for Cisplatin Containing Chemotherapy, in Combination with Enfortumab Vedotin, as Neoadjuvant Treatment and Then Continued After Radical Cystectomy as Adjuvant Treatment

THOMSON REUTERS
·
Aug 05

Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence

Reuters
·
Aug 05